Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs such as Wegovy can access them, states the World Health Organization as it issues its initial advice on the medications.
Given more than one billion individuals worldwide now classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the jabs that can assist patients in reducing substantial body mass, notes the body.
Skinny Jab Scarcity
Even under the present most favorable outlook, the supply of such drugs would only suffice for about 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice calls on countries and companies to increase availability, via approaches such as voluntary licensing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Operate
These medications imitate a body's own hormone to slow digestion, reduce hunger and increase satiety so users reduce food intake.
Patients usually begin shedding pounds within a few weeks of commencing the weekly injections.
Evidence suggests people may put most of the weight back on after a year of halting the drug, because their typical appetite come back.
To be above a healthy weight raises your likelihood for experiencing medical conditions, including diabetes, heart disease, stroke, and some malignancies.
Excess weight concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.
